Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Astrophys J Suppl Ser ; 250(2)2020 Oct.
Article in English | MEDLINE | ID: mdl-34711999

ABSTRACT

Composition and spectra of Galactic cosmic rays (CRs) are vital for studies of high-energy processes in a variety of environments and on different scales, for interpretation of γ-ray and microwave observations, for disentangling possible signatures of new phenomena, and for understanding of our local Galactic neighborhood. Since its launch, AMS-02 has delivered outstanding-quality measurements of the spectra of p ¯ , e ±, and nuclei: 1H-8O, 10Ne, 12Mg, 14Si. These measurements resulted in a number of breakthroughs; however, spectra of heavier nuclei and especially low-abundance nuclei are not expected until later in the mission. Meanwhile, a comparison of published AMS-02 results with earlier data from HEAO-3-C2 indicates that HEAO-3-C2 data may be affected by undocumented systematic errors. Utilizing such data to compensate for the lack of AMS-02 measurements could result in significant errors. In this paper we show that a fraction of HEAO-3-C2 data match available AMS-02 measurements quite well and can be used together with Voyager 1 and ACE-CRIS data to make predictions for the local interstellar spectra (LIS) of nuclei that are not yet released by AMS-02. We are also updating our already-published LIS to provide a complete set from 1H-28Ni in the energy range from 1 MeV nucleon-1 to ~100-500 TeV nucleon-1, thus covering 8-9 orders of magnitude in energy. Our calculations employ the GalProp-HelMod framework, which has proved to be a reliable tool in deriving the LIS of CR p ¯ , e -, and nuclei 1H-8O.

3.
Astrophys J ; 854(2)2018 Feb 20.
Article in English | MEDLINE | ID: mdl-34646044

ABSTRACT

The local interstellar spectrum (LIS) of cosmic-ray (CR) electrons for the energy range 1 MeV to 1 TeV is derived using the most recent experimental results combined with the state-of-the-art models for CR propagation in the Galaxy and in the heliosphere. Two propagation packages, GALPROP and HelMod, are combined to provide a single framework that is run to reproduce direct measurements of CR species at different modulation levels, and at both polarities of the solar magnetic field. An iterative maximum-likelihood method is developed that uses GALPROP-predicted LIS as input to HelMod, which provides the modulated spectra for specific time periods of the selected experiments for model-data comparison. The optimized HelMod parameters are then used to adjust GALPROP parameters to predict a refined LIS with the procedure repeated subject to a convergence criterion. The parameter optimization uses an extensive data set of proton spectra from 1997 to 2015. The proposed CR electron LIS accommodates both the low-energy interstellar spectra measured by Voyager 1 as well as the high-energy observations by PAMELA and AMS-02 that are made deep in the heliosphere; it also accounts for Ulysses counting rate features measured out of the ecliptic plane. The interstellar and heliospheric propagation parameters derived in this study agree well with our earlier results for CR protons, helium nuclei, and anti-protons propagation and LIS obtained in the same framework.

4.
Int J Breast Cancer ; 2017: 1683060, 2017.
Article in English | MEDLINE | ID: mdl-29333297

ABSTRACT

Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged drug-free breaks that leads to antitumor activity. In the present article, we review preclinical and clinical data of metronomic administration of chemotherapy agents with or without biological agents in TNBC cell lines and patients, contextually reporting data from the VICTOR-2 study in the subgroup of patients with TNBC, in order to stimulate new ideas for the design of clinical trials in this subset of patients.

SELECTION OF CITATIONS
SEARCH DETAIL
...